FDA Approves First Generic of Priftin (rifapentine) Tablets
The FDA has approved the first generic version of Priftin (rifapentine) tablets for treating active pulmonary tuberculosis.
Asset / Drug
Drug and asset intelligence for Priftin with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.